DBV Technologies
29 rue du Faubourg
Saint Jacques
Paris
75014
France
Tel: 33-0-1-55-389270
Fax: 33-0-1-41-312882
Website: http://www.dbv-technologies.com/
Email: info@dbv-technologies.com
207 articles about DBV Technologies
-
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
3/2/2023
DBV Technologies announces filing of 2022Annual Report on Form 10-K and 2022Universal Registration Document
-
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
2/27/2023
DBV Technologies announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update.
-
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
2/21/2023
DBV Technologies, a clinical-stage biopharmaceutical company, announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology Annual Scientific meeting, taking place February 24-27 in San Antonio, TX.
-
DBV Technologies to Participate in Upcoming Investor Conference - February 10, 2023
2/10/2023
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023.
-
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
12/23/2022
DBV Technologies announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the Company’s VITESSE Phase 3 clinical trial that will evaluate the modified Viaskin™ Peanut 250 μg patch in peanut-allergic children ages 4 to 7 years.
-
DBV Technologies to Participate in Upcoming Investor Conference - November 22, 2022
11/22/2022
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022.
-
DBV Technologies to Highlight New Clinical Data at ACAAI 2022
11/9/2022
DBV Technologies announced that new clinical data on the use of Viaskin™ Peanut 250 μg in peanut-allergic toddlers ages 1 to 3 years will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, which is being held November 10-14, 2022, in Louisville, KY.
-
DBV Technologies Reports Third Quarter Financial Results and Business Update
11/3/2022
DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the third quarter of 2022.
-
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
10/31/2022
DBV Technologies, a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live audio webcast on Thursday, November 3, at 5:00 p.m. ET to report third quarter 2022 financial results and provide a corporate update.
-
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
10/3/2022
DBV Technologies announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors, was appointed as Chairperson of the Board’s Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022.
-
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
9/21/2022
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical study.
-
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
9/7/2022
DBV Technologies Announces Initiation of Phase 3 Study(VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years.
-
DBV Technologies to Present at Upcoming September 2022 Investor Conferences
9/2/2022
DBV Technologies, a clinical-stage biopharmaceutical company, announced that Daniel Tassé, Chief Executive Officer, DBV Technologies, will participate in upcoming investor conferences in September.
-
DBV Technologies to Participate in Upcoming EAACI 2022 Congress
6/28/2022
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual European Academy of Allergy and Clinical Immunology (EAACI) Annual Scientific meeting, July 1 – 3, 2022, in Prague, Czech Republic.
-
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
6/16/2022
DBV Technologies, a clinical-stage biopharmaceutical company, announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York.
-
DBV Technologies Announces Private Placement Financing of $194 Million
6/9/2022
DBV Technologies, a clinical-stage biopharmaceutical company, announced an aggregate $194 million private investment in public equity financing from the sale of 32,855,669 ordinary shares, as well as pre-funded warrants to purchase up to 28,276,331 ordinary shares.
-
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
6/7/2022
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its pivotal Phase 3 trial EPITOPE (EPIT in TOddlers with PEanut Allergy), assessing the safety and efficacy of Viaskin™ Peanut 250 µg for the treatment of peanut-allergic toddlers ages 1 to 3 years, met its primary endpoint.
-
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting
5/12/2022
DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting.
-
DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
4/25/2022
DBV Technologies announced that the Company will host a conference call and live audio webcast on Thursday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.
-
Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
4/25/2022
DBV Technologies announced that the Company will host a conference call and live audio webcast on Monday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.